T 0814/12 (Target in PI3-kinase pathway/SILENCE THERAPEUTICS) of 20.10.2016

European Case Law Identifier: ECLI:EP:BA:2016:T081412.20161020
Date of decision: 20 October 2016
Case number: T 0814/12
Application number: 03790894.4
IPC class: A61K 38/48
A61P 35/00
G01N 33/573
C12Q 1/37
Language of proceedings: EN
Distribution: D
Download and more information:
Decision text in EN (PDF, 530 KB)
Documentation of the appeal procedure can be found in the Register
Bibliographic information is available in: EN
Versions: Unpublished
Title of application: Use of protein kinase N beta
Applicant name: Silence Therapeutics GmbH
Opponent name: Alnylam Pharmaceuticals Inc.
Board: 3.3.04
Headnote: -
Relevant legal provisions:
European Patent Convention Art 54
European Patent Convention Art 56
European Patent Convention Art 83
European Patent Convention Art 84
European Patent Convention Art 123(2)
European Patent Convention Art 123(3)
European Patent Convention R 115(2)
Rules of procedure of the Boards of Appeal Art 13(1)
Rules of procedure of the Boards of Appeal Art 15(3)
Keywords: -
Catchwords:

-

Cited decisions:
T 0241/95
Citing decisions:
-

Source: http://www.epo.org/law-practice/case-law-appeals/recent/t120814eu1.html

Date retrieved: 17 May 2021

8 references found.

Click X to load a reference inside the current page, click on the title to open in a new page.

EPC Articles

EPC Implementing Rules

Case Law Book: II Conditions to be met by an Application

General Case Law